Bath & Body Works (NYSE:BBWI – Get Free Report) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $3.06-3.26 for the period, compared to the consensus earnings per share estimate of $3.19. The company issued revenue guidance of down 2-4% yr/yr to ~$7.13-7.28 billion, compared to the consensus revenue estimate of $7.25 billion. Bath & Body Works also updated its Q3 guidance to $0.41-0.47 EPS.
Bath & Body Works Price Performance
Bath & Body Works stock opened at $31.74 on Friday. Bath & Body Works has a one year low of $26.20 and a one year high of $52.99. The company’s fifty day moving average price is $31.96 and its two-hundred day moving average price is $40.40. The company has a market capitalization of $6.95 billion, a price-to-earnings ratio of 8.18, a PEG ratio of 0.96 and a beta of 1.77.
Bath & Body Works (NYSE:BBWI – Get Free Report) last announced its earnings results on Wednesday, August 28th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.02. Bath & Body Works had a negative return on equity of 41.94% and a net margin of 12.69%. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.54 billion. As a group, sell-side analysts anticipate that Bath & Body Works will post 3.18 earnings per share for the current year.
Bath & Body Works Announces Dividend
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on BBWI shares. Evercore ISI decreased their price target on shares of Bath & Body Works from $45.00 to $35.00 and set an in-line rating for the company in a report on Wednesday, August 28th. Robert W. Baird lowered their target price on Bath & Body Works from $54.00 to $45.00 and set an outperform rating on the stock in a report on Thursday, August 29th. Citigroup cut their price target on Bath & Body Works from $48.00 to $35.00 and set a neutral rating for the company in a report on Tuesday, August 20th. Morgan Stanley lowered their price objective on shares of Bath & Body Works from $56.00 to $51.00 and set an overweight rating on the stock in a research note on Thursday, September 5th. Finally, UBS Group cut their target price on shares of Bath & Body Works from $52.00 to $38.00 and set a neutral rating for the company in a research note on Thursday, August 29th. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $42.35.
Read Our Latest Stock Report on BBWI
Bath & Body Works Company Profile
Bath & Body Works, Inc operates a specialty retailer of home fragrance, body care, and soaps and sanitizer products. It sells its products under the Bath & Body Works, White Barn, and other brand names through retail stores and e-commerce sites located in the United States and Canada, as well as through international stores operated by partners under franchise, license, and wholesale arrangements.
Featured Stories
- Five stocks we like better than Bath & Body Works
- How to Calculate Inflation Rate
- Is Viking Therapeutics Ready For Another Surge?
- Airline Stocks – Top Airline Stocks to Buy Now
- AI Boom and Rate Cuts Boost Utility Stocks: Best Growth Picks
- How to invest in marijuana stocks in 7 stepsĀ
- Top 3 Homebuilder Stocks to Watch as Rates Drop
Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.